The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
An RNA helicase is an enzyme that unwinds RNA. The unwinding is powered by the helicase's hydrolysis of ATP. RNA helicases are involved holistically in the metabolism of RNA, which is found in all facets of life on Earth.
Prevalence of hepatocellular carcinoma in individuals exposed to aflatoxin increases with co-infection of hepatitis B virus. One study estimated that while individuals with urinary aflatoxin bio-markers were at a threefold greater risk than the normal population for hepatocellular carcinoma; those infected with hepatitis B virus were at a fourfold risk; and those with the aflatoxin bio-markers and infected with hepatitis B virus were at a 60 times greater risk for hepatocellular carcinoma than the normal population.
=== Training === Endocrinologists are specialists of internal medicine or pediatrics. Reproductive endocrinologists deal primarily with problems of fertility and menstrual function—often training first in obstetrics. Most qualify as an internist, pediatrician, or gynecologist for a few years before specializing, depending on the local training system. In the U.S. and Canada, training for board certification in internal medicine, pediatrics, or gynecology after medical school is called residency. Further formal training to subspecialize in adult, pediatric, or reproductive endocrinology is called a fellowship. Typical training for a North American endocrinologist involves 4 years of college, 4 years of medical school, 3 years of residency, and 2 years of fellowship. In the US, adult endocrinologists are board certified by the American Board of Internal Medicine (ABIM) or the American Osteopathic Board of Internal Medicine (AOBIM) in Endocrinology, Diabetes and Metabolism.
Sources: en.wikipedia.org
These variations can be attributed to factors like geographic isolation, strict border controls, lenient laws on illegal items, high prices, tight internet control, and the general accessibility of illegal goods.
== External links == FML – Functional Materials Laboratory of the ETH Zürich Properties and use of magnetic nanoparticle clusters (magnetic nanobeads) Magnetic nanoparticles target human cancer cells Magnetic Nanoparticles Remove Ovarian Cancer Cells from the Abdominal Cavity Wiedwald, U. and Ziemann, P. (Ed.): Properties and applications of magnetic nanoparticles, Thematic Series in the Open Access Beilstein Journal of Nanotechnology. Effects of surfactant on the structural and magnetic properties of hydrothermally synthesized NiFe2O4 nanoparticles
=== Heterogeneous catalysis === Operando spectroscopy is widely applicable to heterogeneous catalysis, which is largely used in industrial chemistry. An example of operando methodology to monitor heterogeneous catalysis is the dehydrogenation of propane with molybdenum catalysts commonly used in industrial petroleum. Mo/SiO2 and Mo/Al2O2 were studied with an operando setup involving EPR/UV-Vis, NMR/UV-Vis, and Raman. The study examined the solid molybdenum catalyst in real time. It was determined that the molybdenum catalyst exhibited propane dehydrogenation activity, but deactivated over time. The spectroscopic data showed that the most likely catalytic active state was Mo4+ in the production of propene. The deactivation of the catalyst was determined to be the result of coke formation and the irreversible formation of MoO3 crystals, which were difficult to reduce back to Mo4+. The dehydrogenation of propane can also be achieved with chromium catalysts, through the reduction of Cr6+ to Cr3+. Propylene is one of the most important organic starting materials is used globally, particularly in the synthesis of various plastics. Therefore, the development of effective catalysts to produce propylene is of great interest. Operando spectroscopy is of great value to the further research and development of such catalysts.
Sources: en.wikipedia.org
The scandal began with revelations of contamination of Sanlu milk products. The New Zealand dairy cooperative Fonterra, which owned a 43% stake in Sanlu, said they were alerted to melamine contamination on 2 August (almost a month before the issue became public), and have said to have pushed hard for a full public recall. Although there was an immediate trade recall, Fonterra said that local administrators refused an official recall. A Fonterra director had given Sanlu management a document detailing the European Union's permitted levels of melamine, but Fonterra chief executive Andrew Ferrier has stated that at no time did Fonterra say small amounts of melamine were acceptable.
The optimal ranges for estrogen apply only to individuals taking estradiol (or an ester of estradiol), and not to those taking synthetic or other non-bioidentical preparations (e.g., conjugated estrogens or ethinylestradiol). Physicians also recommend broader medical monitoring, including complete blood counts; tests of renal function, liver function, and lipid and glucose metabolism; and monitoring of prolactin levels, body weight, and blood pressure. If prolactin levels are greater than 100 ng/mL, estrogen therapy should be stopped and prolactin levels should be rechecked after 6 to 8 weeks. If prolactin levels remain high, an MRI scan of the pituitary gland to check for the presence of a prolactinoma should be ordered. Otherwise, estrogen therapy may be restarted at a lower dosage. Cyproterone acetate is particularly associated with elevated prolactin levels, and discontinuation of cyproterone acetate lowers prolactin levels. In contrast to cyproterone acetate, estrogen and spironolactone therapy is not associated with increased prolactin levels.
=== Chairmen === Chairman of the Anti-Fascist Council of People's Liberation of Bosnia and Herzegovina Vojislav Kecmanović (25 November 1943 – 26 April 1945) Chairmen of the Presidium of the People's Assembly Vojislav Kecmanović (26 April 1945 – November 1946) Đuro Pucar (November 1946 – September 1948) Vlado Šegrt (September 1948 – March 1953) Chairmen of the People's Assembly Đuro Pucar (December 1953 – June 1963) Ratomir Dugonjić (June 1963 – July 1967) Džemal Bijedić (1967 – July 1971) Hamdija Pozderac (July 1971 – May 1974) Chairmen of the Presidency Ratomir Dugonjić (May 1974 – April 1978) Raif Dizdarević (April 1978 – April 1982) Branko Mikulić (April 1982 – 26 April 1984) Milanko Renovica (26 April 1984 – 26 April 1985) Munir Mesihović (26 April 1985 – April 1987) Mato Andrić (April 1987 – April 1988) Nikola Filipović (April 1988 – April 1989) Obrad Piljak (April 1989 – 20 December 1990) Alija Izetbegović (20 December 1990 – 8 April 1992)
In the 2020s, conservative politicians in state legislatures introduced a growing number of bills that restrict the rights of LGBTQ people, especially transgender people. A strong supporter of LGBTQ rights, Harris denounced legislative attacks on transgender rights in states across the country. Exit polls showed that Harris had an 86%-12% advantage over Trump among voters who say that they are gay, lesbian, bisexual or transgender. Harris' lead among this group is the largest for a 21st-century Democratic presidential candidate with those reporting to be gay, lesbian, bisexual or transgender (2016–2024) and gay/lesbian/bisexual respondents (2000–2008). Exit poll results for the 2012 election are not available. Trump promised to roll back policies regarding transgender individuals. Harris and Walz campaigned as supporters of LGBTQ+ rights. Trump stated he would rescind Biden's Title IX protections "on day one" for transgender students using bathrooms, locker rooms, and pronouns that align with their gender identities. Trump stated he would enact a federal law that would recognize only two genders and claimed that being transgender is a concept only recently manufactured by "the radical left". Trump previously withdrew Title IX provisions that allowed transgender youth to have access to the bathrooms of their choice, and he attempted to roll-back several transgender-related policies in the Affordable Care Act. Trump repeated a false claim that children undergo transgender surgery while at school, without parental knowledge or consent.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.